Introducing SERB Pharmaceuticals

SERB Pharmaceuticals represents the combination of SERB, BTG Specialty Pharmaceuticals and Veriton Pharma to form a new, growing specialty pharmaceutical company focused on emergency care and rare diseases.

We make treating complex and life-threatening conditions possible; supporting clinicians, healthcare systems and governments while offering hope to patients and their families.

Who we are

SERB began in the 1950s as Société d’Études et de Recherches Biologiques (Company for Biologic Study and Research).

Today SERB has the broadest antidote portfolio in the world, including medical countermeasures for chemical, biological, radiological and nuclear (CBRN) risks.

As a fully integrated company, we have the experience and capabilities to acquire, develop, and manufacture our medicines to the highest standards, and make them available worldwide through our secure supply chain.

Improving patients’ quality of life and offering hope is what motivates and inspires us.

80+

Medicines

470+

Dedicated employees

Direct sales in

18

countries

Supplying

100+

countries

Latest news

  • 02 August 2024
    FDA has accepted a BLA for bentracimab, the first and only ticagrelor reversal agent, for filing and priority review
    Pleasanton, CA and Philadelphia, PA – 2 August 2024: SFJ Pharmaceuticals, (SFJ), Sponsor of the bentracimab Biologics License Application (BLA), and SERB Pharmaceuticals (SERB), who acquired exclusive US rights to bentracimab from SFJ and will commercialize bentracimab in the United States, announced today that the US Food and Drug Administration (FDA) has accepted the bentracimab […]
  • 31 July 2024
    SERB Pharmaceuticals strengthens leadership in medical countermeasures with the global acquisition of RSDL® (Reactive Skin Decontamination Lotion) kit for $75 million
    Philadelphia, PA, 31 July 2024: SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today the acquisition of RSDL® (Reactive Skin Decontamination Lotion) kit from Emergent BioSolutions Inc. (NYSE: EBS) for an up-front payment of approximately $75 million. In addition, SERB will pay Emergent a $5 million payment upon first achievement of a milestone relating to […]
  • 30 May 2024
    SERB Pharmaceuticals appoints Vanessa Wolfeler as CEO to drive next stage of the company’s growth
    SERB appoints Vanessa Wolfeler as its new Chief Executive Officer

Latest insight

SERB publishes first Sustainability Report

Our first Sustainability Report is an important milestone in the company’s efforts to measure and improve our performance around environmental, social, and governance (ESG) issues.

Read more
You are leaving the SERB.com global corporate website
This link will take you to a third-party website, the terms of use and the privacy policy of which may be different. SERB declines all responsibility in that regard and in case of a breach of its privacy policy by the third-party website. Moreover, SERB is not responsible for any information or opinion contained in any third-party website.
Choose your region